



# “Oral Factor Xa Inhibition and Stroke Prevention”

February 12<sup>th</sup> 2011  
9:00am-12:00pm  
Holiday Inn Yorkdale  
Toronto Ontario, Canada

Co – Chairs:  
Dr. Gupta, MD  
Dr. Verma, MD

Faculty:  
Dr. Atul Verma, MD  
Dr. Manesh Patel, MD  
Dr. Jeffrey Weitz, MD



## Meeting Objectives:

1. To discuss the latest evidence surrounding stroke prevention, with a focus on understanding in which patient new anticoagulant options should be considered.
2. To highlight current knowledge gaps and opportunities for further research and CME initiatives in anticoagulant decision making for stroke prevention.

## AGENDA

Dr. Milan Gupta	Opening Remarks
Dr. Atul Verma	Time in a Therapeutic Range – How Do We Define Optimal Warfarin Use?
Dr. Manesh Patel	Rivaroxaban – A New Era in Stroke Prevention
Dr. Jeffrey Weitz	Warfarin, Dabigatran, Rivaroxaban – Selecting the Right Drug for the Right Patient
Dr. Subodh Verma	Group Discussion